ArticleAntimicrobial agents and chemotherapy2017
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Registry-linked trialAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06419296 (Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.), which is not on this map. Cited by 173 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
Who cites it
173 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.Annals of medicine · 2024Pooled it
- Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Infection · 2018Pooled it
- Breaking the deadlock of metallo-β-lactamases: evidence and prospects for Aztreonam/Avibactam.Emerging microbes & infections · 2026Review
- Multi-carbapenemase-producing Klebsiella pneumoniae: Genomic characterization and In Vitro evaluation of cefiderocol and novel β-lactam/β-lactamase inhibitor combinations.Molecular biology reports · 2026Article
- The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC-antimicrobial resistance · 2026Review
- Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales.Journal of clinical microbiology · 2026Article
- Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistantAntimicrobial agents and chemotherapy · 2026Article
- Clinical Characteristics and Outcomes of Bloodstream Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales in Argentina: A Subanalysis of the EMBARCAR Prospective Multicenter Cohort Study.Open forum infectious diseases · 2026Article
- Avibactam-based combinations for the treatment of multidrug resistant Gram-negative bacilli infections.Le infezioni in medicina · 2026Review
- Article
- Evaluation of the In Vitro Synergistic Activity of Ceftazidime/Avibactam AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Continuity of carbapenem resistance determinants in carioca river and Rodrigo de Freitas Lagoon, Rio de Janeiro, Brazil, after decade.Scientific reports · 2025Article
- Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDRAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Mortality of metallo-β-lactamase-producing Enterobacterales bacteremias with combined ceftazidime-avibactam plus aztreonam vs. other active antibiotics: a multicenter target trial emulation.Lancet regional health. Americas · 2025Article
- Combatting mobile colistin-resistant (MCR), metallo-β-lactamase (MBL)-producingJAC-antimicrobial resistance · 2025Article
- The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam.Antimicrobial agents and chemotherapy · 2025Article
- The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam.Antimicrobial agents and chemotherapy · 2025Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Steven MarshallLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Andrea M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Laura J RojasLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Krisztina M Papp-WallaceLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Romney M HumphriesDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Brad SpellbergDivision of Infectious Diseases, Keck School of Medicine at USC and the Los Angeles County-USC Medical Center, Los Angeles, California, USA.
Kristine M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Emma K MarshallLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Susan D RudinLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Federico PerezLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Brigid M WilsonLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Ronald B WassermanInfectious Disease Doctors Medical Group, Walnut Creek, California, USA.
Linda ChikowskiJohn Muir Health, Walnut Creek, California, USA.
David L PatersonThe University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia.
Alejandro J VilaInstituto de Biología Molecular y Celular de Rosario Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina, Universidad Nacional de Rosario, Rosario, Argentina.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
Barry N KreiswirthPublic Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark, New Jersey, USA.
Henry F ChambersUniversity of California, San Francisco, and San Francisco General Hospital, San Francisco, California, USA.
Vance G FowlerDivision of Infectious Diseases, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Michael R JacobsDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Mark E PulseUniversity of North Texas Health Science Center, Fort Worth, Texas, USA.
William J WeissUniversity of North Texas Health Science Center, Fort Worth, Texas, USA.
Robert A BonomoLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA robert.bonomo@va.gov.
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MTransferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7MMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NCATS NIH HHS UL1 TR001863NIAID NIH HHS HHSN272201500007CNIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI117211NIAID NIH HHS R21 AI114508NIAID NIH HHS UM1 AI104681
Abstract
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). Disk diffusion and agar-based antimicrobial susceptibility testing were initially performed to determine the
Indexed as
AnimalsAnti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamasesbeta-Lactam ResistanceCeftazidimeColony Count, MicrobialCyclophosphamideDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationEnterobacteriaceaeEnterobacteriaceae InfectionsFemaleGene ExpressionAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeCyclophosphamideDrug Combinationsavibactamaztreonamceftazidimedisk diffusionmetallo-β-lactamases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06419296ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.